Abstract
SARS-CoV-2 Delta and Omicron are globally relevant variants of concern (VOCs). While individuals infected with Delta are at risk to develop severe lung disease, Omicron infection often causes milder symptoms, especially in vaccinated individuals1,2. The question arises whether the current rampant spread of Omicron could lead to future cross-variant protection, accelerating the end of the pandemic. Here we show that without vaccination, infection with Omicron induces a limited humoral immune response in mice and humans. Sera from mice overexpressing the human ACE2 receptor and infected with Omicron neutralize only Omicron, but no other VOCs, while Delta infection elicits broad cross-variant neutralization. This is not observed with the WA1 ancestral isolate, although exposure to both, WA1 and Delta, but not Omicron, cause high-level viral replication, pro-inflammatory cytokine expression, exhaustion of lung-resident T cells and severe disease in infected animals. Analysis of human sera from unvaccinated, Omicron-infected individuals confirms limited neutralization of other variants besides Omicron itself, while sera from Omicron breakthrough cases show robust cross-variant neutralization in vaccinated individuals. Together, our results indicate that Omicron infection enhances preexisting immunity elicited by vaccines, but on its own may not confer broad protection against Non-Omicron variants in unvaccinated individuals.
Competing Interest Statement
A.M.S. and J.A.D. are inventors on a patent application filed by the Gladstone Institutes and the University of California that covers the method and composition of SARS-CoV-2 VLP preparations for RNA transduction and expression in cells. J.A.D. is a cofounder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics, and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Vertex, Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, Algen Biotechnologies, Felix Biosciences, The Column Group, and Inari. J.A.D. is a director at Johnson & Johnson and Tempus and has research projects sponsored by Biogen, Pfizer, AppleTree Partners, and Roche. C.Y.C. is the director of the UCSF-Abbott Viral Diagnostics and Discovery Study and receives research support from Abbott Laboratories. C.Y.C. also receives support for SARS-CoV-2 research unrelated to this study from Mammoth Biosciences.
Funding Statement
This research is funded by grants from the National Institutes of Health: NIAID R37AI083139 to M.O., NIH/NIAID (F31 AI164671-01) to I.P.C., NHLBI U54HL147127 to M.M. A.M.S is supported by Natural Sciences and Engineering Research Council of Canada (NSERC PDF-533021-2019). M.O. and W.C.G also received support from the Roddenberry Foundation and M.O. received a gift from Pam and Ed Taft. J.A.D. acknowledges support from the National Institutes of Health (R21AI59666) and support from the Howard Hughes Medical Institute and the Gladstone Institutes. N.R. acknowledges support from the Van Auken Private Foundation, David Henke, and Pamela and Edward Taft; and Awards #2164 and #2208 from Fast Grants, a part of Emergent Ventures at the Mercatus Center, George Mason University. C.Y.C thanks the staff at UCSF Clinical Laboratories and the UCSF Clinical Microbiology Laboratories for help in identifying and aliquoting nasal swab and plasma samples. CYC acknowledges support by the Innovative Genomics Institute (IGI) at UC Berkeley and UC San Francisco, US Centers for Disease Control and Prevention contract 75D30121C10991, Abbott Laboratories, and the Sandler Program for Breakthrough Biomedical Research at UCSF. We thank Stanley Tamaki and Claudia Bispo for CyTOF assistance at the Parnassus Flow Core, and the lab of Eliver Ghosn for guidance on lung cell processing. We thank the Gladstone Histology Core. The group also acknowledges support from the James B. Pendleton Charitable Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Advarra and UCSF gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
